Ariad Pharm under pressure; may be attributed to NVS application submition for LDK378 in US (8.04)
NVS confirmed a regulatory application was submitted in the US for LDK378 (ceritinib), a potent and selective oral anaplastic lymphoma kinase (ALK) inhibitor, in ALK positive non-small cell lung cancer.